Insmed Incorporated

NASDAQ:INSM

Biotechnology

Healthcare
$119.80 -2.77%

-$2.73 today

Market cap
$26.28B
Beta
0.77
P/E (TTM)
-17.4
EPS (TTM)
-$5.49
52W Low $90.39High $212.75

Volume 1.94M

Average 3.31M

INSM Net Receivables

Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.

Insmed IncorporatedNASDAQ: INSM

Net Receivables · Q2 FY2026 · quarter ended Jun 2026

Net receivables rises 291.3% from a year ago

Net receivables stood at $215.33M at the end of Q2 FY2026, up 291.3% from a year earlier and up 20.6% from the prior quarter. Over 3 fiscal years it compounded at +68.0% a year.

Context

  • Net receivables amounted to 10.2% of total assets at the end of Q2 FY2026, up 8.0 pp from a year earlier.
  • Net receivables increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether net receivables keeps rising in the next quarterly balance sheet after a +291.3% change from a year earlier.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterJun 2026
$215.33M+20.6% QoQ
Last fiscal yearDec 2025
$140.86M+170.8% YoY
Year agoJun 2025
$55.03M+291.3% since
Net Receivables past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+291.3%——
1 year+170.8%——
3-year CAGR+68.0%——
5-year CAGR——
10-year CAGR——

Net Receivables history

USD · from the balance sheet

Latest · FY2025
140.86M USD
Year-over-year change
+170.8%
4-year CAGR
+55.1%

Net Receivables vs competitors

How INSM compares with its peers on the latest reported figures

  • INSM's Jun 2026 net receivables of $215.33M is the 2nd highest of the 4 companies compared; the peer median is $108.58M.
  • Its year-over-year change of +291.3% is the 2nd highest of 4, against a peer median of +1.5%.
  • Net receivables amounts to 10.2% of total assets for INSM, versus a peer median of 4.3%.
INSM Competitors Peer median
Net Receivables for INSM and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
UTHRUnited Therapeutics CorporationJun 2026$310.3M -18.2%+16.7%4.3%
INSMInsmed IncorporatedJun 2026$215.33M +291.3%+68.0%10.2%
LQDALiquidia CorporationJun 2026$108.58M +989.3%+120.9%20.8%
TBPHTheravance Biopharma, Inc.Mar 2026$15.58M +1.5%+78.5%3.3%
AVLNAvalyn Pharma Inc. Common Stock—— ———
Peer median (excluding INSM) $108.58M+1.5%+78.5%4.3%

Competitors are the stored peer set for INSM. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents716.78M1.07B482.37M555.03M510.45M
Short-term Investments074.24M298.07M878.8M919.6M
Net Receivables24.35M29.71M41.19M52.01M140.86M
Inventory67.01M69.92M83.25M98.58M132.07M
Other Current Assets025.47M24.18M37.25M91.24M
Total Current Assets837.04M1.27B929.06M1.62B1.79B
Property, Plant & Equipment (Net)95.52M102.08M104.39M115.58M139.21M
Goodwill136.11M136.11M136.11M136.11M136.11M
Intangible Assets73.81M68.76M63.7M58.65M97.65M
Long-term Investments50.04M0000
Tax Assets00000
Other Non-current Assets50.99M76.1M96.57M93.23M97.38M
Total Non-current Assets406.47M383.05M400.77M403.57M470.35M
Total Assets1.24B1.66B1.33B2.03B2.26B
Account Payables35.78M50.46M65.39M73.03M79.91M
Short-term Debt00016.5M19.26M
Tax Payables00000
Deferred Revenue00000
Other Current Liabilities33.46M42.74M55.63M127.69M258.19M
Total Current Liabilities135.17M190.24M225.63M297.53M468.87M
Long-term Debt566.59M1.13B1.16B1.26B716M
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)00000
Other Non-current Liabilities95.74M208.5M242.78M144.7M307.81M
Total Non-current Liabilities697.87M1.38B1.44B1.44B1.06B
Total Liabilities833.04M1.57B1.66B1.74B1.53B
Common Stock1.19M1.36M1.48M1.79M2.14M
Retained Earnings(2.27B)(2.7B)(3.45B)(4.36B)(5.64B)
Accumulated OCI968K756K(745K)(2.29M)1.46M
Other Stockholders Equity00000
Minority Interest00000
Total Equity410.47M87.95M(331.92M)285.38M738.98M
Total Debt612.27M1.18B1.2B1.31B768.16M
Net Debt(104.51M)103.83M721.62M759.09M257.71M

Insmed Incorporated

NASDAQ:INSM

Intrinsic Alpha fair value

Locked

Current Price

$119.80

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.